A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery

Condition:   Ocular Inflammation and Pain Interventions:   Drug: APP13007, 0.05%;   Drug: APP13007, 0.1%;   Drug: APP13007 Placebo, 0.05%;   Drug: APP13007 Placebo, 0.1% Sponsor:   Formosa Pharmaceuticals, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials